

Cannabis-based products for medicinal use

Consultation on draft scope – deadline for comments is 5pm on Tuesday 4 December 2018

email: CannabisMedUse@nice.org.uk

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly or arrive after the deadline.</p> <p>In addition to your comments below, we would like to hear your views on these questions:</p> <ol style="list-style-type: none"> 1. Are there any cost saving interventions or examples of innovative approaches that should be considered for inclusion in this guideline? <p>Developing NICE guidance: how to get involved has a list of possible areas for comment on the draft scope.</p>
Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):	Royal Pharmaceutical Society
Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	We are not funded by the Tobacco industry
Name of person completing form:	Wing Tang

Type		[for office use only]		Comments
Comment No.	Page number	Line number	Insert each comment in a new row. Do not paste other tables into this table, as your comments could get lost – type directly into this table.	
Example	3	55	The draft scope currently excludes people who have already been diagnosed. We feel this group should be included because....	
1	General	"Areas that will not be covered"	The usefulness of this guideline to prescribers will be limited by synthetic cannabinoids being outside of scope. This will mean the need for clinicians to refer to multiple guidelines when supporting the patient which will undermine the value of this guideline for decision-making and safe and effective prescribing. The guideline will be more useful if medicinal products with marketing authorisations were included in pathways together with cannabis based medicinal products without marketing authorisations.	
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				

Please add extra rows as needed

Please return to: CannabisMedUse@nice.org.uk

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

13			
14			
15			

Add extra rows if needed

Checklist for submitting comments

- Use this form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, do not include attachments such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments.

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.

Please add extra rows as needed

Please return to: CannabisMedUse@nice.org.uk

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.